All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

PHARMACOMPASS

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

Product Type

Companies

Hyloris Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

BELGIUM Belgium

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Hyloris Pharmaceuticals Announces Intention to Launch an Initial Public Offering on Euronext Brussels

Lead Product(s): Acetaminophen/Paracetamol,Ibuprofen

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Public Offering June 03, 2020

Details:

The IPO is expected to provide the Company with the resources needed to finance the development of its existing portfolio of product candidates, as well as establish a commercial infrastructure in the United States for its IV Cardiovascular portfolio.